DS
ELDN icon

DRW Securities’s Eledon Pharmaceuticals ELDN Stock Holding History

DRW Securities’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,027
Closed -$129K – 63
2018
Q2 		$129K Buy
1,027
+166
+19% +$17.2K 0.01% 83
2018
Q1 		$78K Buy
861
+167
+24% +$12.3K 0.01% 154
2017
Q4 		$51K Buy
+694
New +$52.4K 0.01% 448

Other funds holding ELDN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAMU
Amundi Asset Management US Boston, Massachusetts $131B AUM 73.57% 1-Year Est. Return

DRW Securities's ELDN Position: Q3 2018 in Review

DRW Securities sold out of Eledon Pharmaceuticals (ELDN) in Q3 2018, closing a stake of 1,027 shares — an estimated $129K sold.

DRW Securities first reported a position in ELDN in Q4 2017 and held it in 3 quarters. The position peaked at $129K in Q2 2018. 20 funds tracked by Wall St. Rank hold ELDN as of Q3 2018.

  • DRW Securities reported no remaining Eledon Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • DRW Securities sold 1,027 Eledon Pharmaceuticals shares in Q3 2018, an estimated $129K.
  • DRW Securities first reported a position in Eledon Pharmaceuticals in Q4 2017 and held it in 3 quarters.
  • DRW Securities's Eledon Pharmaceuticals position peaked at $129K in Q2 2018.
  • 20 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2018.

Based on DRW Securities's 13F filing for Q3 2018, filed 14 Nov 2018.